Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
    • CHEST 2021
    • IDWeek 2021
    • IAS 2021
    • ADA 2021
    • ATS 2021
    • ACC 2021
    • ACP 2021
    • AAN 2021
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
    • CHEST 2021
    • IDWeek 2021
    • IAS 2021
    • ADA 2021
    • ATS 2021
    • ACC 2021
    • ACP 2021
    • AAN 2021

Methotrexate

  • You have access
    Methotrexate in rheumatoid arthritis: when NSAIDs fail
    John A. Flynn, MD and David B. Hellmann, MD
    Cleveland Clinic Journal of Medicine November 1995, 62 (6) 351-359;

    With diligent monitoring, low-dose methotrexate is effective for treating selected patients with rheumatoid arthritis, and it is safer than previously thought.

  • You have access
    Response of immunoregulatory lymphocyte subsets to methotrexate in rheumatoid arthritis
    Leonard H. Calabrese, DO, John V. Taylor, MD, William S. Wilke, MD, Allen M. Segal, DO, Rafael Valenzuela, MD, PhD and John D. Clough, MD
    Cleveland Clinic Journal of Medicine May 1990, 57 (3) 232-241;
  • You have access
    Methotrexate for corticosteroid-resistant polymyalgia rheumatica and giant cell arteritis
    Patricia L. Krall, PA-C, Daniel J. Mazanec, MD and William S. Wilke, MD
    Cleveland Clinic Journal of Medicine May 1989, 56 (3) 253-257;
  • You have access
    Drug-induced osteoporosis
    Daniel J. Mazanec, MD and Joseph M. Grisanti, MD
    Cleveland Clinic Journal of Medicine May 1989, 56 (3) 297-303;
  • You have access
    Methotrexate in the treatment of arthritis and connective tissue diseases
    William S. Wilke, M.D., Jeffrey A. Biro, D.O. and Allen M. Segal, D.O.
    Cleveland Clinic Journal of Medicine July 1987, 54 (4) 327-338;
  • You have access
    Hepatotoxicity of prolonged methotrexate therapy for rheumatoid arthritis
    Allen H. Mackenzie, M.D.
    Cleveland Clinic Journal of Medicine June 1985, 52 (2) 129-135;
  • You have access
    Childhood-onset pityriasis rubra pilaris treated with methotrexate administered intravenously
    C. William Hanke, M.D. and Willard D. Steck, M.D.
    Cleveland Clinic Journal of Medicine June 1983, 50 (2) 201-203;

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2023 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire